Monday, April 06, 2020 8:56:17 AM
The rest of the story:Feel free to submit this text and previous text to Cris Sipes and JT at respective email addresses: Anyone or 2 volunteers?
Post-trial settlement agreement is available, particularly when the lower court judgment is not final—e.g., an appeal from that judgment is pending. I will be surprised if you find/think to the contrary.
Note paragraph (c) of FRCP 68, sub-titled “Offer after Liability is Determined”.
H and R liability to A so far is $0.00, but the loss of A’s personal property(its 6 patents containing certain claims that issued with a presumption of validity that embraced activities from which Amarin received or will receive extensive $$ revenue is very real) is damage in terms of $$. The “extent of liability remains to be determined by further proceedings”, namely the appeal to the Fed. Cir.
I have terms that I am considering for such a contract or settlement agreement that I think all parties will agree to. Once signed, the settlement agreement ( it differs from a consent decree) is entered in the docket with no input from the judge, and the case closes, making the appeal moot.
What are the terms of agreement?
A summary, not final:
1) Amarin agrees to license each of R and H to practice all claims of the 6 patents with therapies currently under consideration by the FDA in ANDAs already filed with FDA, but not yet approved. Amarin could even assign the 6 patents to H and R making them owners of those patents, and very willing to sue other generics to keep those generics out of the Marine market. Ownership of the patents could be divided 3 ways, each of A, H and R having a 1/3 interest. Amarin by contract retains its rights to market Vascepa for the Marine indication.
A retains all rights in its remaining ~45 Orange Book patents to enforce against entry by anyone into market to practice or treat for R-I indications and results. Those patents have claims and FDA labels sufficient to embrace both Marine and R-I, so others think. The claims of those patents contain limitations not present in adjudicated claims.
2) A, H and R join in agreement that the district court, Judge D, made errors of fact and law, making her decision unlikely to be upheld on appeal( this sounds and reads well but is useless against the public or others wishing to come to market. I know of no way that litigants can agree that a patent is valid in the face of a district judge who has adjudicated otherwise. This proviso 2 can be left out or deleted for now to see what Federal Circuit does.) Or what D.J. D does in light of 3):
3) A request for reconsideration, no reference to FRCP 68, but with proper signatures in place on paragraph 1) that is enforceable by state court judges:
3) H and R agree to join any timely request for reconsideration filed by A, asking withdrawal by J. D of a) her judgment and decision, and b) issuing a new 1 page opinion that overturns her previous opinion for reasons advanced by(.....) and c) issuing a new judgment that the patents are valid and infringed.
*************
I do not know J. D’s pride in work product, but I think that, faced with all parties to suit agreeing that her original decision, for reasons both in fact and law, was wrong, she might agree to the relief requested.
The delays that might be built into the judicial, FDA and market systems by Cov-19 are unknown as well as unknowable in time length. E.g., work at home, arguments postponed until further notice. Market building by Amarin will be difficult too—DTC ads ineffective as Vascepa Brand builders because new consumers are not traveling anywhere and doctors offices are closed until further notice. More use for Teledoc perhaps. R and H could be forbidden to refer to Vascepa in all marketing ploys they might come up with eventually. I have not figured a way to forbid them and customers from providing product, or refuse to supply doctors or hospitals for treatment of CVDs
Enough for now. These ideas are not final and have not been seen by anyone
******************
Marjac's reply:
I absolutely think that post-trial settlement is possible.
I think the substance of your proposal is brilliant. Intellectually sublime.
One thing though, I think the docketing of the Appeal with the Federal Circuit would divest Judge Du of jurisdiction to reconsider, unless, perhaps, they settle, jointly move for a remand, and then she enters the reconsideration Order.
Do you have good contacts at Amarin[or Covington] to provide with your proposal?
I have not checked bold reply of Marjac.
However, I do recall a case in CCPA where I served as bailiff. An attorney approached the lectern, and said:
Your honors, the parties to this case have settled. This case need not be heard today.
Chief Judge: Do you have signed agreement saying that?
Attorney: Yes, and presents to court to read.
Chief Judge: After reading, passes signed document to colleagues on bench, who nod their heads.
Chief Judge: this case is settled, and will not be heard today. You can go home(to attorney). Next case is.....
Post-trial settlement agreement is available, particularly when the lower court judgment is not final—e.g., an appeal from that judgment is pending. I will be surprised if you find/think to the contrary.
Note paragraph (c) of FRCP 68, sub-titled “Offer after Liability is Determined”.
H and R liability to A so far is $0.00, but the loss of A’s personal property(its 6 patents containing certain claims that issued with a presumption of validity that embraced activities from which Amarin received or will receive extensive $$ revenue is very real) is damage in terms of $$. The “extent of liability remains to be determined by further proceedings”, namely the appeal to the Fed. Cir.
I have terms that I am considering for such a contract or settlement agreement that I think all parties will agree to. Once signed, the settlement agreement ( it differs from a consent decree) is entered in the docket with no input from the judge, and the case closes, making the appeal moot.
What are the terms of agreement?
A summary, not final:
1) Amarin agrees to license each of R and H to practice all claims of the 6 patents with therapies currently under consideration by the FDA in ANDAs already filed with FDA, but not yet approved. Amarin could even assign the 6 patents to H and R making them owners of those patents, and very willing to sue other generics to keep those generics out of the Marine market. Ownership of the patents could be divided 3 ways, each of A, H and R having a 1/3 interest. Amarin by contract retains its rights to market Vascepa for the Marine indication.
A retains all rights in its remaining ~45 Orange Book patents to enforce against entry by anyone into market to practice or treat for R-I indications and results. Those patents have claims and FDA labels sufficient to embrace both Marine and R-I, so others think. The claims of those patents contain limitations not present in adjudicated claims.
2) A, H and R join in agreement that the district court, Judge D, made errors of fact and law, making her decision unlikely to be upheld on appeal( this sounds and reads well but is useless against the public or others wishing to come to market. I know of no way that litigants can agree that a patent is valid in the face of a district judge who has adjudicated otherwise. This proviso 2 can be left out or deleted for now to see what Federal Circuit does.) Or what D.J. D does in light of 3):
3) A request for reconsideration, no reference to FRCP 68, but with proper signatures in place on paragraph 1) that is enforceable by state court judges:
3) H and R agree to join any timely request for reconsideration filed by A, asking withdrawal by J. D of a) her judgment and decision, and b) issuing a new 1 page opinion that overturns her previous opinion for reasons advanced by(.....) and c) issuing a new judgment that the patents are valid and infringed.
*************
I do not know J. D’s pride in work product, but I think that, faced with all parties to suit agreeing that her original decision, for reasons both in fact and law, was wrong, she might agree to the relief requested.
The delays that might be built into the judicial, FDA and market systems by Cov-19 are unknown as well as unknowable in time length. E.g., work at home, arguments postponed until further notice. Market building by Amarin will be difficult too—DTC ads ineffective as Vascepa Brand builders because new consumers are not traveling anywhere and doctors offices are closed until further notice. More use for Teledoc perhaps. R and H could be forbidden to refer to Vascepa in all marketing ploys they might come up with eventually. I have not figured a way to forbid them and customers from providing product, or refuse to supply doctors or hospitals for treatment of CVDs
Enough for now. These ideas are not final and have not been seen by anyone
******************
Marjac's reply:
I absolutely think that post-trial settlement is possible.
I think the substance of your proposal is brilliant. Intellectually sublime.
One thing though, I think the docketing of the Appeal with the Federal Circuit would divest Judge Du of jurisdiction to reconsider, unless, perhaps, they settle, jointly move for a remand, and then she enters the reconsideration Order.
Do you have good contacts at Amarin[or Covington] to provide with your proposal?
I have not checked bold reply of Marjac.
However, I do recall a case in CCPA where I served as bailiff. An attorney approached the lectern, and said:
Your honors, the parties to this case have settled. This case need not be heard today.
Chief Judge: Do you have signed agreement saying that?
Attorney: Yes, and presents to court to read.
Chief Judge: After reading, passes signed document to colleagues on bench, who nod their heads.
Chief Judge: this case is settled, and will not be heard today. You can go home(to attorney). Next case is.....
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
